Camptothecin | CAS:7689-03-4 | Manufacturer ChemFaces

Camptothecin

ChemFaces products have been cited in many studies from excellent and top scientific journals

Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Tech: service@chemfaces.com
Order: manager@chemfaces.com
Address: 176, CheCheng Eest Rd., WETDZ, Wuhan, Hubei 430056, PRC

How to Order

Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Order: manager@chemfaces.com

Delivery time

Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal

Citing Use of our Products

More Impact Factor than five Cite...

* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.

According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.

Size /Price /Stock	10 mM * 1 mL in DMSO / $10.8 / In-stock
Other Packaging	*Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap

Featured Products

More...

4-Hydroxybenzyl alcohol

Catalog No: CFN97071
CAS No: 623-05-2
Price: $30/20mg

Corynantheine

Catalog No: CFN92843
CAS No: 18904-54-6
Price: $ / mg

Zearalenone

Catalog No: CFN91172
CAS No: 17924-92-4
Price: $50/20mg

Mangiferin

Catalog No: CFN98719
CAS No: 4773-96-0
Price: $40/20mg

Vicenin -3

Catalog No: CFN92032
CAS No: 59914-91-9
Price: $198/20mg

Gallic acid

Catalog No: CFN99624
CAS No: 149-91-7
Price: $30/20mg

(-)-Epigallocatechin(EGC)

Catalog No: CFN97549
CAS No: 970-74-1
Price: $40/20mg

Madecassic acid

Catalog No: CFN99914
CAS No: 18449-41-7
Price: $30/20mg

Flavone

Catalog No: CFN70130
CAS No: 525-82-6
Price: $30/20mg

Salvianolic acid A

Catalog No: CFN99161
CAS No: 96574-01-5
Price: $128/20mg

Description:

Camptothecin is a specific inhibitor of DNA topoisomerase I (Topo I) with IC50 of 0.68 μM; it is a novel alkaloidal leukemia and tumor inhibitor, is a strong inhibitor of nucleic acid synthesis in mammalian cells and a potent inducer of strand breaks in chromosomal DNA. Camptothecin and its analogs reduce amyloid-β production and amyloid-β42-induced IL-1β production.

Targets:

Beta Amyloid | p53 | IL Receptor | Topoisomerase

In vitro:

J Alzheimers Dis. 2015;43(2):465-77.

Camptothecin and its analogs reduce amyloid-β production and amyloid-β42-induced IL-1β production.[Pubmed: 25096614]

Compounds derived from natural products are becoming promising alternative drugs/tools in Alzheimer's disease (AD) therapeutics.
METHODS AND RESULTS:
From an in-house natural products library, seventeen hits were selected for their inhibitory effect on the production of amyloid-β (Aβ) with IC50 lower than 10 μM without causing obvious toxicity. Among these compounds, Camptothecin (CPT) and its analogs showed inhibitory effects on amyloid-β 1-42 (Aβ42) with the IC50 value in the nanomolar range in HEKsw cells and SHSY5Ysw cells. Further studies showed that CPT and its analogs inhibited Aβ42 via a p53 dependent pathway. Meanwhile, CPT and its analogs could also inhibit Aβ42 induced IL-1β production in the THP-1 cells.
CONCLUSIONS:
Taken together, our results indicate that CPT and its analogs would be a promising therapeutic candidates for AD.

In vivo:

J Drug Target. 2014 Dec;22(10):913-26.

Development and evaluation of magnetic microemulsion: tool for targeted delivery of camptothecin to BALB/c mice-bearing breast cancer.[Pubmed: 25119147]

Development and evaluation of Camptothecin-loaded-microemulsion (ME) and -magnetic microemulsion (MME) for passive/active-targeted delivery to BALB/c mice-bearing breast cancer.
METHODS AND RESULTS:
Based on the pseudo-ternary phase diagrams Camptothecin-loaded-MEs and -MMEs were developed using benzyl alcohol:Captex 300 (3:1), TPGS:Tween 80 (2:1) and water. Furthermore, characterized for their droplet size distribution, magnetic susceptibility and effect of droplet size in plasma and evaluated for in vitro and in vivo targeting potential, drug release, haemolytic potential, cytotoxicity, genotoxicity, in vivo biodistribution and lactone ring stability. Drug-loaded MEs showed uniform droplet distribution, extended drug release (76.07 ± 4.30% at 24 h), acceptable level of haemolytic activity (<20%), significant cytotoxicity (129 ± 3.9 ng/mL) against MCF-7 cancer cells and low DNA damage in lymphocytes. Targeting potential of MMEs was documented in 4T1 breast cancer-induced BALB/c mice. MMEs were concentrated more at the target tissue on introduction of external magnetic field. In vivo biodistribution study documented the active targeting of 5067.56 ± 354.72 ng/gm and passive targeting of 1677.58 ± 134.20 ng/gm Camptothecin to breast cancer from MME and ME, respectively. Lactone stability study shows around 80% of the lactone stable at 24 h.
CONCLUSIONS:
Developed ME and MME may act as a promising nanocarrier for efficient targeting of breast cancer tissues.

Camptothecin Description

Source:	The barks of Camptotheca acuminata Decne.
Solvent:	Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Storage:	Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C). Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
After receiving:	The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.

Kinase Assay:

Nanomedicine. 2014 Oct;10(7):1477-86.

Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer.[Pubmed: 24768630]

CRLX101 is a nanopharmaceutical consisting of cyclodextrin-based polymer molecule and Camptothecin. The CRLX101 nanoparticle is designed to concentrate and slowly release Camptothecin in tumors over an extended period of time.
METHODS AND RESULTS:
Tumor biopsy and blood samples collected from patients with advanced solid malignancies before and after CRLX101 treatment are subjected to immunohistochemistry and pharmacogenomics. The expression of Topoisomerase-1, Ki-67, CaIX, CD31 and VEGF decreased after CRLX101 treatment. The expressions of these proteins are inversely proportional with survival duration of the patients. The Drug Metabolism Enzymes and Transporters (DMET) array shows an allele frequency in patients similar to global populations with none of the SNPs associated with toxicity. The results suggest that the observed lower toxicity is not likely to be due to different genotypes in SNPs. CRLX101 demonstrates a promising anti-tumor activity in heavily pre-treated or treatment-refractory solid tumor malignancies presumably by inhibition of proliferation and angiogenesis correlating with tumor growth inhibition. From the clinical editor: In this cancer treatment study clinical samples collected from patients were subjected to immunohistochemistry and pharmacogenomics.
CONCLUSIONS:
The expressions of key proteins that are inversely proportional with survival duration of the patients decreased after treatment with CRLX101, a Camptothecin slow-release nanoparticle conjugate. This anti-tumor activity in heavily pre-treated and treatment resistant solid tumors, promises a novel therapeutic approach.

J Biol Chem. 1985 Nov 25;260(27):14873-8.

Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.[Pubmed: 2997227]

Camptothecin, a cytotoxic drug, is a strong inhibitor of nucleic acid synthesis in mammalian cells and a potent inducer of strand breaks in chromosomal DNA.
METHODS AND RESULTS:
Neither the equilibrium dialysis nor the unwinding measurement indicates any interaction between Camptothecin and purified DNA. However, Camptothecin induces extensive single strand DNA breaks in reactions containing purified mammalian DNA topoisomerase I. DNA breakage in vitro is immediate and reversible. Analyses of Camptothecin-induced DNA breaks show that topoisomerase I is covalently linked to the 3' end of the broken DNA. In addition, Camptothecin inhibits the catalytic activity of mammalian DNA topoisomerase I. We propose that Camptothecin blocks the rejoining step of the breakage-reunion reaction of mammalian DNA topoisomerase I. This blockage results in the accumulation of a cleavable complex which resembles the transient intermediate proposed for eukaryotic DNA topoisomerase I.
CONCLUSIONS:
The inhibition of nucleic acid synthesis and the induction of DNA strand breaks observed in vivo may be related to the formation of this drug-induced cleavable complex.

Product Name	Camptothecin
Price:	$30 / 20mg
CAS No.:	7689-03-4
Catalog No.:	CFN97249
Molecular Formula:	C₂₀H₁₆N₂O₄
Molecular Weight:	348.4 g/mol
Purity:	>=98%
Type of Compound:	Alkaloids
Physical Desc.:	Powder
Source:	The barks of Camptotheca acuminata Decne.
Solvent:	Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Download:	COA MSDS SDF Manual
Similar structural:	Comparison (Web) (SDF)
Guestbook:

Size /Price /Stock	10 mM * 100 uL in DMSO / Inquiry / In-stock 10 mM * 1 mL in DMSO / Inquiry / In-stock
Related Libraries	Anticancer Compound Library Cytotoxic Compound Library Antileukaemic Compound Library Alkaloids Compound Library Topoisomerase Inhibitor Library p53 Inhibitor Library IL Receptor Inhibitor Library Beta Amyloid Inhibitor Library

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	2.8703 mL	14.3513 mL	28.7026 mL	57.4053 mL	71.7566 mL
5 mM	0.5741 mL	2.8703 mL	5.7405 mL	11.4811 mL	14.3513 mL
10 mM	0.287 mL	1.4351 mL	2.8703 mL	5.7405 mL	7.1757 mL
50 mM	0.0574 mL	0.287 mL	0.5741 mL	1.1481 mL	1.4351 mL
100 mM	0.0287 mL	0.1435 mL	0.287 mL	0.5741 mL	0.7176 mL

CFN90309	9-Aminocamptothecin	91421-43-1	363.37	C₂₀H₁₇N₃O₄
CFN99735	(S)-10-Hydroxycamptothecin	19685-09-7	364.35	C₂₀H₁₆N₂O₅
CFN90157	10-Methoxycamptothecin	19685-10-0	378.38	C₂₁H₁₈N₂O₅
CFN93013	Rubitecan	91421-42-0	393.35	C₂₀H₁₅N₃O₆
CFN90439	10-Nitro-camptothecin	104195-61-1	393.34	C₂₀H₁₅N₃O₆
CFN90462	Topotecan hydrochloride	119413-54-6	457.9	C₂₃H₂₄ClN₃O₅
CFN90886	Irinotecan hydrochloride	100286-90-6	623.2	C₃₃H₃₉ClN₄O₆
CFN90336	7-Ethylcamptothecin	78287-27-1	376.41	C₂₂H₂₀N₂O₄
CFN90335	7-Ethyl-10-Hydroxycamptothecin	86639-52-3	392.4	C₂₂H₂₀N₂O₅
CFN99729	9-Methoxycamptothecine	39026-92-1	378.38	C₂₁H₁₈N₂O₅